ORGO / Organogenesis Holdings Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Filing Fee Table

Calculation of Filing Fee Tables S-8 Organogenesis Holdings Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Class A Common Stock, $0.0001 par value per share Other 15,900,000 $ 4.485 $ 71,311,500.00 0.0001531 $ 10

Power of Attorney (included on the signature page hereto)

S-8 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 7, 2025 REGISTRATION NO.

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., (August 7, 2025) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 ORGANOGENESIS HOLD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

Fourth Amendment to Credit Agreement dated as of August 5, 2025 by and among the Company, the lenders named therein and the administrative agent

Exhibit 10.1 Execution Version FOURTH AMENDMENT TO CREDIT AGREEMENT This Fourth Amendment to Credit Agreement (this “Amendment”) dated and effective as of August 5, 2025 (the “Fourth Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (the “Borrower”), the several banks and other financial institutions or entities party hereto constituting the Required Lende

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2025 ORGANOGENESIS HOLDI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results CANTON, Mass., (May 8, 2025) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

First Amendment to Lease dated March 21, 2025 among Organogenesis Holdings Inc., Organogenesis Inc., and DIV Technology Way, LLC

Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of March 21, 2025, by and between DIV TECHNOLOGY WAY, LLC, a Delaware limited liability company (“Landlord”), and ORGANOGENESIS HOLDINGS INC., a Delaware corporation and ORGANOGENESIS INC., Delaware corporation (collectively, jointly and severally, “Tenant”). R E C I T A L S: A. Landlord and T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 ORGANOGENESIS HOLDING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss

FORWARD LOOKING STATEMENTS & OTHER IMPORTANT CAUTIONS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecas

Exhibit 99.1 INVESTOR PRESENTATION March 2025 FORWARD LOOKING STATEMENTS & OTHER IMPORTANT CAUTIONS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results CANTON, Mass., (February 27, 2025) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports med

Employee Letter Agreement dated as of July 30, 2021 by and between Organogenesis Inc. and Robert Cavorsi

July 30, 2021 Robert Cavorsi Dear Rob, Congratulations! I am pleased to inform you that you have been recommended for a promotion and it has been approved.

Organogenesis Holdings Inc. Amended and Restated Insider Trading Compliance Policy

Exhibit 19.1 ORGANOGENESIS HOLDINGS INC. AMENDED AND RESTATED INSIDER TRADING COMPLIANCE POLICY Updated April 19, 2023 CONTENTS Page I. SUMMARY 1 II. STATEMENT OF POLICIES PROHIBITING INSIDER TRADING 1 III. EXPLANATION OF INSIDER TRADING 2 IV. STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING 6 V. ADDITIONAL PROHIBITED TRANSACTIONS 9 VI. RULE 10b5-1 TRADING PLANS, SECTION 16 AND RULE 144 11 VII.

Subsidiaries of Organogenesis Holdings Inc.

Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland

Form of Performance Share Award Agreement under the 2018 Equity Incentive Plan

Exhibit 10.36 ORGANOGENESIS HOLDINGS INC. Performance Share Award Agreement Organogenesis Holdings Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”), hereby grants this Performance Share Award (this “Award”) to the Recipient named below. The terms and conditions of this Award are set forth in this Performance Share Award Agreement (this “Agreement”), consisting of this

Description of Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the capital stock of Organogenesis Holdings Inc. (the “Company,” “we,” “us,” and “our”) and the material provisions of our restated certificate of incorporation, as amended (“restated certificate of incorporation”), our certificate of designati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2025 ORGANOGENESIS H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

Lease dated as of November 18, 2024 by and between DIV Technology Way, LLC and Organogenesis Holdings Inc.

Exhibit 10.35 Execution Copy LEASE between DIV TECHNOLOGY WAY, LLC, as Landlord and ORGANOGENESIS HOLDINGS INC. and ORGANOGENESIS INC., as Tenant 100 Technology Way Smithfield, Rhode Island November 18, 2024 TABLE OF CONTENTS ARTICLE 1 GRANT 1 ARTICLE 2 TERM 3 ARTICLE 3 COMPLETION AND OCCUPANCY OF THE PREMISES 4 ARTICLE 4 RENT AND SECURITY 4 ARTICLE 5 ADDITIONAL RENT FOR REAL ESTATE TAXES AND OPER

Up to 130,000 Shares of Series A Convertible Preferred Stock Offered by the Selling Stockholders Up to 34,285,653 Shares of Class A Common Stock Issuable Upon Conversion of Series A Convertible Preferred Stock

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-283934 PROSPECTUS Up to 130,000 Shares of Series A Convertible Preferred Stock Offered by the Selling Stockholders Up to 34,285,653 Shares of Class A Common Stock Issuable Upon Conversion of Series A Convertible Preferred Stock On November 12, 2024, we consummated a private placement (the “Private Placement”) pursuan

Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021

Acceleration Request Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 December 20, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Organogenesis Holdings Inc.   Registration Statement on Form S-3   File No. 333-283934   Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated u

As filed with the Securities and Exchange Commission on December 19, 2024

Table of Contents As filed with the Securities and Exchange Commission on December 19, 2024 Registration Statement No.

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Organogenesis Holdings Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 27, 2024 ORGANOGENESIS H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 27, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Stock Repurchase Agreement, dated November 27, 2024, by and between Organogenesis Holdings Inc. and GN 2016 Family Trust u/a/d August 12, 2016 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on December 2, 2024)

Exhibit 10.1 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 27, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and GN 2016 Family Trust u/a/d August 12, 2016 (the “Selling Stockholder”). Recitals WHEREAS, the Selling Stockholder has expressed interest to the Company (the “Indication of Interest

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Organogenesis Expands Manufacturing Capacity to Support Future Growth CANTON, Mass.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 18, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Power of Attorney of David Burgstahler and Thompson Dean (filed herewith)

EX-99.4 3 d896717dex994.htm EX-99.4 Exhibit 99.4 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Benjamin Silbert with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: 1. execute for and on behalf of the undersigned with respect to Organogenesis Holdings Inc. (the “Company”), Schedules 13D and 13G and Forms 3, 4,

ORGO / Organogenesis Holdings Inc. / Avista Healthcare Partners III, L.P. - SC 13D Activist Investment

SC 13D 1 d896717dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Organogenesis Holdings Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Avista Healthcare Partners 65 East 55th Street, 18th Floor New Yor

Joint Filing Agreement, dated November 19, 2024, by and among Avista Healthcare Partners III, LP, AHP III Orchestra Holdings, L.P., Avista Capital Partners VI GP, L.P., Avista Capital Managing Member VI, LLC, David Burgstahler and Thompson Dean (filed herewith)

EX-99.1 2 d896717dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 13d-1(k)(1) thereunder, the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13(d) of the Exchange Act or any rule or regulation thereunder (

STOCK REPURCHASE AGREEMENT

EX-99.20 4 d899462dex9920.htm EX-99.20 Exhibit 99.20 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and Glenn H. Nussdorf (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by

ORGO / Organogenesis Holdings Inc. / Soleus Capital Master Fund, L.P. - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea0221047-13ga3soleusorgan.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ORGANOGENESIS HOLDINGS INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68621F102 (CUSIP Number) September 30, 2024 (Date of Event Whi

ORGO / Organogenesis Holdings Inc. / Ades Alan A. - SC 13D/A Activist Investment

SC 13D/A 1 d899462dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Chief Administrative and Legal Officer Organogenesis Holdi

STOCK REPURCHASE AGREEMENT

EX-99.19 3 d899462dex9919.htm EX-99.19 Exhibit 99.19 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and Albert Erani (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by and a

STOCK REPURCHASE AGREEMENT

EX-99.18 2 d899462dex9918.htm EX-99.18 Exhibit 99.18 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and Alan A. Ades (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by and a

STOCK REPURCHASE AGREEMENT

EX-99.22 6 d899462dex9922.htm EX-99.22 Exhibit 99.22 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and RED Holdings, LLC (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by

STOCK REPURCHASE AGREEMENT

EX-99.21 5 d899462dex9921.htm EX-99.21 Exhibit 99.21 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and the Alan Ades 2014 GRAT (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreeme

Organogenesis Holdings Inc. Announces $130 million Private Placement Offering of Series A Convertible Preferred Stock Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Announces $130 million Private Placement Offering of Series A Convertible Preferred Stock Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases CANTON, Mass. (November 12, 2024) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regene

Subscription Agreement, dated November 12, 2024, by and among Organogenesis Holdings Inc., Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on November 13, 2024)

Exhibit 10.1 Execution Version SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (the “Agreement”) is entered into this 12th day of November, 2024, by and among, Organogenesis Holdings Inc., a Delaware corporation (the “Company”), Avista Healthcare Partners III, L.P., a Delaware limited partnership (“Avista Onshore”) and AHP III Orchestra Holdings, L.P., a Delaware limited partnership (“Avista Ho

Form of Stock Repurchase Agreement, dated November 12, 2024 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on November 13, 2024)

Exhibit 10.3 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and [] (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by and among the Company, Avista Healthcare Partners III,

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Third Amendment to Credit Agreement dated as of November 12, 2024 by and among the Company, the lenders named therein and the administrative agent (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on November 13, 2024)

Exhibit 10.2 Execution Version THIRD AMENDMENT TO CREDIT AGREEMENT This Third Amendment to Credit Agreement (this “Amendment”) dated and effective as of November 12, 2024 (the “Third Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (the “Borrower”), the several banks and other financial institutions or entities party hereto constituting the Required Lende

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results CANTON, Mass., (November 12, 2024) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported fina

Certificate of Designations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on November 12, 2024)

Organogenesis Holdings Inc. Certificate of Designations Series A Convertible Preferred Stock November 12, 2024 IF " DOCVARIABLE "SWDocIDLocation" 1" = "1" " DOCPROPERTY "SWDocID" 12596845.1" "" 12596845.1 Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 14 Section 3. The Convertible Preferred Stock 14 (a) Designation; Par Value 14 (b) Number of Authorized Shares 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021

Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 August 13, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Organogenesis Holdings Inc. Registration Statement on Form S-3 File No. 333-281392 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 19

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Organogenesis Holdings Inc.

As filed with the Securities and Exchange Commission on August 8, 2024

Table of Contents As filed with the Securities and Exchange Commission on August 8, 2024 Registration Statement No.

Form of Indenture

Exhibit 4.1 ORGANOGENESIS HOLDINGS INC. INDENTURE Dated as of    , 20  [    ] Trustee TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.01 Issuable in Series 6 Section 2.02 Esta

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss

Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results CANTON, Mass., (August 8, 2024) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

2018 Equity Incentive Plan (as amended)

Exhibit 10.1 ORGANOGENESIS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN Section 1. Purposes of the Plan The purposes of the Organogenesis Holdings Inc. 2018 Equity Incentive Plan (the “Plan”) are to (i) provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Organogenesis Holdings Inc. (the “Company”) and its Subsidiaries (as de

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 20, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commission

Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results CANTON, Mass., (May 9, 2024) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Exhibit 99.1 Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case April 3, 2024 at 7:30 AM EDT CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mar

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 3, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi

Organogenesis Holdings Inc. Compensation Recovery Policy as adopted on November 1, 2023

ORGANOGENESIS HOLDINGS INC. Compensation Recovery Policy November 1, 2023 This Compensation Recovery Policy (the “Policy”) has been adopted by the Board of Directors (the “Board”) of Organogenesis Holdings Inc. (the “Company”). Certain capitalized terms used in this Policy are defined at the end of this Policy. 1. Introduction. This Policy is intended to support the Company’s pay-for-performance p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):February 29, 2024 ORGANOGENESIS HO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):February 29, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commi

Subsidiaries of Organogenesis Holdings Inc.

Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance CANTON, Mass., (February 29, 2024) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

ORGO / Organogenesis Holdings Inc. / Soleus Capital Master Fund, L.P. - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea192415-13ga2soleusorgan.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Organogenesis Holdings Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 68621F102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commi

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results CANTON, Mass., (November 9, 2023) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported finan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance CANTON, Mass., (August 9, 2023) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Me

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2023 ORGANOGENESIS HOLDI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 ORGANOGENESIS HOLDIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissio

Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results CANTON, Mass., (May 10, 2023) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial

Second Amendment to Credit Agreement dated and effective as of April 17, 2023 by and among Organogenesis Holdings Inc., as borrower, the several banks and other financial institutions or entities party hereto and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), as the Administrative Agent (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 10, 2023)

Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT This Second Amendment to Credit Agreement (this “Amendment”) dated and effective as of April 17, 2023 (the “Second Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (the “Borrower”), the several banks and other financial institutions or entities party hereto constituting the Required Lenders (as defined in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Organogenesis Holdings Inc. Reports Fourth Quarter 2022and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter 2022and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance CANTON, Mass., (March 1, 2023) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

First Amendment to Credit Agreement dated as of December 8, 2022 by and among Organogenesis Holdings Inc., as borrower, the several banks and other financial institutions or entities party hereto and Silicon Valley Bank, as the Administrative Agent, and as the Issuing Lender and the Swingline Lender (incorporated by reference to Exhibit 10.33 to the Company’s Annual Report on Form 10-K (File No. 001-37906) filed with the SEC on March 1, 2023)

EXHIBIT 10.33 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT This First Amendment to Credit Agreement (this “Amendment”) dated and effective as of December 8, 2022 (the “First Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (the “Borrower”), the several banks and other financial institutions or entities party hereto (the “Lenders”) and SILICON VAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):March 1, 2023 ORGANOGENESIS HOLDIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):March 1, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissio

Subsidiaries of Organogenesis Holdings Inc.

Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland

ORGO / Organogenesis Holdings Inc / Soleus Capital Master Fund, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 d458587dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Organogenesis Holdings Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 68621F102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria

ORGO / Organogenesis Holdings Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Organogenesis Holdings Inc.

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 9, 2022

S-8 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 9, 2022 REGISTRATION NO.

Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results

FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results CANTON, Mass., (November 9, 2022) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):November 9, 2022 ORGANOGENESIS HOL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):November 9, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commis

ORGO / Organogenesis Holdings Inc / Soleus Capital Master Fund, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Organogenesis Holdings Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 68621F102 (CUSIP Number) October 11, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

JOINT FILING AGREEMENT

EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Mr. Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results CANTON, Mass., (August 9, 2022) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financ

2018 Equity Incentive Plan (as amended) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on June 21, 2024)

Exhibit 10.1 ORGANOGENESIS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN Section 1. Purposes of the Plan The purposes of the Organogenesis Holdings Inc. 2018 Equity Incentive Plan (the ?Plan?) are to (i) provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Organogenesis Holdings Inc. (the ?Company?) and its Subsidiaries (as de

Certificate of Amendment of Certificate of Incorporation of Organogenesis Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on June 27, 2022)

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ORGANOGENESIS HOLDINGS INC. Organogenesis Holdings Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That the Board of Directors of the Corporation duly adopted resolutions setting forth the proposed amendment

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissio

Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results CANTON, Mass., (May 10, 2022) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors CANTON, Mass., May 5, 2022 ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today annou

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ TRANSITION REPORT PUR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents PRELIMINARY PROXY STATEMENT ? SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Other Events, Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 15, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ TRANSITION REPORT PURSU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

Subsidiaries of Organogenesis Holdings Inc.

Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland

Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance CANTON, Mass., (March 1, 2022) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surg

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 1, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors CANTON, Mass., February 17, 2022 ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the ap

ORGO / Organogenesis Holdings Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 29, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

ORGO / Organogenesis Holdings Inc / Ades Alan A. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02

ORGO / Organogenesis Holdings Inc / Ades Alan A. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Appoints Prathyusha Duraibabu to Board of Directors CANTON, Mass., November 22, 2021 ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION R

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS

Three Months Ended September 30,

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter and First Nine Months 2021 Financial Results CANTON, Mass. (November 9, 2021) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commi

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commis

Purchase and Sale Agreement dated as of August 11, 2021 by and between Organogenesis Inc. and 275 Dan Road SPE, LLC

Exhibit 10.1 Execution Version PURCHASE AND SALE AGREEMENT (275 DAN ROAD, CANTON, MASSACHUSETTS) THIS PURCHASE AND SALE AGREEMENT (the ?Agreement?) is made this 11th day of August, 2021 (the ?Effective Date?), by and between ORGANOGENESIS INC., a Delaware corporation (?Buyer?), and 275 DAN ROAD SPE, LLC, a Delaware limited liability company (?Seller?). WITNESSETH: WHEREAS, Seller is the owner of t

Credit Agreement dated and effective as of August 6, 2021 among Organogenesis Holdings Inc., as borrower, Organogenesis Inc. and Prime Merger Sub, LLC, as guarantors, and Silicon Valley Bank, as Administrative Agent, Lead Arranger, Bookrunner, Issuing Lender and Swingline Lender, and Silicon Valley Bank and the several other lenders from time to time party thereto, collectively as Lenders.

Exhibit 10.1 Execution Version SENIOR SECURED CREDIT FACILITIES CREDIT AGREEMENT dated as of August 6, 2021, among ORGANOGENESIS HOLDINGS INC., as the Borrower, THE SEVERAL LENDERS FROM TIME TO TIME PARTY HERETO, SILICON VALLEY BANK, as Administrative Agent, Joint Lead Arranger, Bookrunner, Issuing Lender and Swingline Lender and BANK OF AMERICA, N.A., CITIZENS BANK N.A. and PNC CAPITAL MARKETS LL

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.

Organogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results CANTON, Mass. (August 9, 2021) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today r

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss

Organogenesis Holdings Inc. Announces New $200 Million Credit Agreement with Silicon Valley Bank

Exhibit 99.2 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Announces New $200 Million Credit Agreement with Silicon Valley Bank CANTON, Mass. (August 9, 2021) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets,

ORGO / Organogenesis Holdings Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

ORGO / Organogenesis Holdings Inc / Ades Alan A. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02021 Tel:

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 24, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissio

ORGO / Organogenesis Holdings Inc / Avista Acquisition Corp. - SC 13DA Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No. 5) (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Organogenesis Holdings Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Cl

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Change in Control Retention Agreement between Organogenesis Holdings Inc. and Gary S. Gillheeney, Sr. effective as of May 10, 2021 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 10, 2021)

Exhibit 10.2 CHANGE IN CONTROL RETENTION AGREEMENT This Change in Control Retention Agreement (this ?Agreement?) is entered into as of May 10, 2021, by and between Organogenesis Holdings Inc., a Delaware corporation with its principal offices located at 85 Dan Road, Canton, Massachusetts 02021 (together with its successors and assigns, the ?Company?), and Gary S. Gillheeney, Sr. (the ?Executive?).

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorp

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC

CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE CORRECTING and REPLACING ? Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) ? In a release issued under the same headline earlier today by Organogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third bullet of the First Quarter 2021 Financial Results Summary, the net revenue from th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class o

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02

Form of Change in Control Retention Agreement (Non-CEO Executive Officers) (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 10, 2021)

Exhibit 10.3 CHANGE IN CONTROL RETENTION AGREEMENT This Change in Control Retention Agreement (this ?Agreement?) is entered into as of [DATE], by and between Organogenesis Holdings Inc., a Delaware corporation with its principal offices located at 85 Dan Road, Canton, Massachusetts 02021 (together with its successors and assigns, the ?Company?), and [name of executive] (the ?Executive?). WHEREAS,

Form of Change in Control Retention Agreement (Independent Directors) (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 10, 2021)

Exhibit 10.4 CHANGE IN CONTROL RETENTION AGREEMENT This Change in Control Retention Agreement (this ?Agreement?) is entered into as of [DATE], by and between Organogenesis Holdings Inc., a Delaware corporation with its principal offices located at 85 Dan Road, Canton, Massachusetts 02021 (together with its successors and assigns, the ?Company?), and [name of board member] (the ?Director?). WHEREAS

Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results CANTON, Mass. (May 10, 2021) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial

Fifth Amendment to Credit Agreement dated and effective as of May 5, 2021 among Organogenesis Holdings Inc., Organogenesis Inc. and Prime Merger Sub, LLC, collectively as borrower, and Silicon Valley Bank, in its capacity as the Issuing Lender and Swingline Lender, Silicon Valley Bank, as Administrative Agent, and Silicon Valley Bank and the other lenders listed therein, collectively as Lenders.

Exhibit 10.1 FIFTH AMENDMENT TO CREDIT AGREEMENT This Fifth Amendment to Credit Agreement (this ?Amendment?) dated and effective as of May 5, 2021 (the ?Fifth Amendment Effective Date?) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (?Holdings?), ORGANOGENESIS INC., a Delaware corporation (?Organogenesis?) and PRIME MERGER SUB, LLC, a Delaware limited liability company (?Prime?,

Organogenesis Appoints Jon Giacomin to Board of Directors

Exhibit 99.2 FOR IMMEDIATE RELEASE Organogenesis Appoints Jon Giacomin to Board of Directors CANTON, Mass., May 10, 2021 ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Gi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commission

Annual Report - 10-K/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

Fourth Amendment to Credit Agreement dated March 31, 2021 among Organogenesis Holdings Inc., Organogenesis Inc. and Prime Merger Sub, LLC, collectively as borrower, and Silicon Valley Bank, in its capacity as the Issuing Lender and Swingline Lender, Silicon Valley Bank, as Administrative Agent, and Silicon Valley Bank and the other lenders listed therein, collectively as Lenders.

Exhibit 10.1 FOURTH AMENDMENT TO CREDIT AGREEMENT This Fourth Amendment to Credit Agreement (this ?Amendment?) is dated and effective as of March 31, 2021 (the ?Fourth Amendment Effective Date?) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (?Holdings?), ORGANOGENESIS INC., a Delaware corporation (?Organogenesis?) and PRIME MERGER SUB, LLC, a Delaware limited liability company (

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss

Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance CANTON, Mass. (March 16, 2021) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

Subsidiaries of Organogenesis Holdings Inc.

Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 16, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Offer Letter dated January 15, 2021 between the Company and David C. Francisco (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on February 16, 2021)

Exhibit 10.1 January 13, 2021 David Francisco Dear Dave, This letter is to offer you the position of Chief Financial Officer of Organogenesis Holdings Inc. (the ?Company?), reporting to the Company?s Chief Executive Officer. This offer is contingent on completion of a satisfactory background and reference check. Your first day of employment with the Company (your ?Start Date?) is expected to be Mo

Organogenesis Appoints David C. Francisco as Chief Financial Officer

EX-99.1 FOR IMMEDIATE RELEASE Organogenesis Appoints David C. Francisco as Chief Financial Officer CANTON, Mass., February 16, 2021 — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announces the appointment of D

Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020

EX-99.1 2 d931089dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020 CANTON, Mass. (January 13, 2021) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wou

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C

Submission of Matters to a Vote of Security Holders - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 18, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (

Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healt

Corporate Presentation December 2020 STRICTLY CONFIDENTIAL Exhibit 99.1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms ?Organogenesis,? ?Company,? ?we,? ?us? and ?our? refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation, and its subsidiaries.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 10, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

- DEF 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

ORGO / Organogenesis Holdings Inc. / Ades Alan A. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02

ORGO / Organogenesis Holdings Inc. / Avista Acquisition Corp. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (

Fee Letter Agreement dated November 12, 2020 by and among the Company, the Avista Funds and the Management Company (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on November 18, 2020)

EX-10.1 Exhibit 10.1 November 12, 2020 Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 Attn: Gary S. Gillheeney, Sr., President and Chief Executive Officer Re: Fee Letter Agreement Ladies and Gentlemen: This fee letter agreement (the “Agreement”) confirms the agreement by and among Organogenesis Holdings Inc. (the “Company”), Avista Capital Partners IV, L.P. (“Avista IV”), Avis

17,500,000 Shares Class A Common Stock

424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-249531 PROSPECTUS 17,500,000 Shares Class A Common Stock We are offering 17,500,000 shares of our Class A common stock. Our Class A common stock is listed on the Nasdaq Capital Market under the symbol “ORGO.” On November 12, 2020, the last reported sale price of our Class A common stock was $3.67 per share. Investing in

As filed with the Securities and Exchange Commission on November 10, 2020.

S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 10, 2020.

Power of Attorney, relating to Robert Ades

EX-24.2 Exhibit 24.2 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the individual whose signature appears below constitutes and appoints each of Gary S. Gillheeney, Sr. and Henry Hagopian as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any a

Power of Attorney, relating to David Erani

Exhibit 24.3 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the individual whose signature appears below constitutes and appoints each of Gary S. Gillheeney, Sr. and Henry Hagopian as such person?s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person?s name, place and stead, in any and all capacities, to sign any and all a

-

CORRESP November 10, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Re: Organogenesis Holdings Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-249531 Acceleration Request Requested Date: November 12, 2020 Requested Time: 4:00 p.m. Eastern Daylight Time Ladies and Gentlemen: As representati

Form of Underwriting Agreement

Exhibit 1.1 [?] Shares Organogenesis Holdings Inc. Class A Common Stock, $0.0001 par value UNDERWRITING AGREEMENT [?], 2020 MORGAN STANLEY & CO. LLC SVB LEERINK LLC As Representatives (the ?Representatives?) of the Several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, N.Y. 10036 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, N.Y. 10019 Dear Sirs: 1. Intro

-

CORRESP Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 November 10, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Organogenesis Holdings Inc. Registration Statement on Form S-1 File No. 333-249531 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C

Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results CANTON, Mass. (November 9, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine market

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS

Shareholder Director Nominations - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C

Power of Attorney (previously filed)

S-1 Table of Contents As filed with the Securities and Exchange Commission on October 16, 2020.

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 14, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C

Organogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020 CANTON, Mass. (October 14, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine market

1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Hea

EX-99.1 0 Exhibit 99.1 Corporate Presentation September 20200 Exhibit 99.1 Corporate Presentation September 2020 1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Com

Organogenesis Holdings Inc. Announces Management Change

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Announces Management Change CANTON, Mass. (August 24, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the resignati

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 18, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commis

Separation Letter Agreement, dated August 24, 2020, between Organogenesis Holdings Inc. and Timothy M. Cunningham (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on August 24, 2020)

EX-10.1 Exhibit 10.1 August 24, 2020 Timothy M. Cunningham Dear Tim: The purpose of this letter agreement (the “Agreement”) is to confirm the terms regarding your separation of employment with Organogenesis Holdings Inc. (together with its subsidiaries, the “Company”). 1. Separation of Employment. You acknowledge that your employment with the Company terminated without cause effective August 18, 2

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Co

Organogenesis Holdings Inc. Reports Second Quarter and First Half 2020 Financial Results

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter and First Half 2020 Financial Results CANTON, Mass. (August 10, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets

Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healt

EX-99.2 Corporate Presentation August 2020 Exhibit 99.2 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation, and its subsidiaries. References in t

Quarterly Report - 10-Q

10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 15, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healt

EX-99.2 Corporate Presentation July 2020 Exhibit 99.2 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation, and its subsidiaries. References in thi

Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020 CANTON, Mass. (July 15, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, t

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commi

Organogenesis Holdings Inc. Reports First Quarter 2020 Financial Results

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2020 Financial Results CANTON, Mass. (May 11, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported fi

Quarterly Report - 10-Q

10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 11, 2020)

EX-10.4 Exhibit 10.4 RESTRICTED STOCK UNIT AGREEMENT Granted by Organogenesis Holdings Inc. Under the 2018 Equity Incentive Plan Organogenesis Holdings Inc. (the “Company”) hereby grants to the person named below (the “Recipient”) restricted stock units (“Restricted Stock Units”), with each such unit representing the right to receive one share of Stock, pursuant to the terms set forth below (the “

Annual Report - 10-K/A

10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

Summary of Amendment to Severance for Gary S. Gillheeney, Sr. (incorporated by reference to Exhibit 10.43 to the Company’s Annual Report on Form 10-K/A (File No. 001-37906) filed with the SEC on April 29, 2020)

EX-10.43 Exhibit 10.43 Summary of Amendment to Severance for Gary S. Gillheeney, Sr. Pursuant to the terms of that certain Amended and Restated Key Employee Agreement dated February 1, 2007 by and between Organogenesis Inc. (the “Company”) and Gary S. Gillheeney, Sr., as amended (the “Agreement”), in connection with a termination of Mr. Gillheeney’s employment by the Company other than for Cause (

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Organogenesis Holdings Inc. Reports Preliminary Revenue Results for First Quarter 2020 Withdraws Fiscal Year 2020 Revenue Guidance Announces May 11, 2020 Earnings Conference Call

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Preliminary Revenue Results for First Quarter 2020 Withdraws Fiscal Year 2020 Revenue Guidance Announces May 11, 2020 Earnings Conference Call CANTON, Mass. (April 8, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization

Third Amendment to Credit Agreement dated March 26, 2020 among Organogenesis Holdings Inc., Organogenesis Inc. and Prime Merger Sub, LLC, collectively as borrower, and Silicon Valley Bank, in its capacity as the Issuing Lender and Swingline Lender, Silicon Valley Bank, as Administrative Agent, and Silicon Valley Bank and the other lenders listed therein, collectively as Lenders (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on March 30, 2020)

EX-10.1 Exhibit 10.1 THIRD AMENDMENT TO CREDIT AGREEMENT This Third Amendment to Credit Agreement (this “Amendment”) dated and effective as of March 26, 2020 (the “Third Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (“Holdings”), ORGANOGENESIS INC., a Delaware corporation (“Organogenesis”) and PRIME MERGER SUB, LLC, a Delaware limited liability company

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 26, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Com

Separation Letter Agreement, dated March 13, 2020, between Organogenesis Holdings Inc. and Howard P. Walthall, Jr. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on March 16, 2020)

EX-10.1 Exhibit 10.1 March 13, 2020 Howard P. Walthall, Jr. Dear Howard: The purpose of this letter agreement (the “Agreement”) is to confirm the terms regarding your separation of employment with Organogenesis Holdings Inc. (together with its subsidiaries, the “Company”). 1. Separation of Employment. You acknowledge that your employment with the Company terminated without Cause effective March 10

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Com

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

Subsidiaries of Organogenesis Holdings Inc.

EX-21.1 Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland

Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation. References in this present

EX-99.2 Corporate Presentation March 2020 Exhibit 99.2 Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation. References in this presentation to the “Business Combination” refer to the consummation of the transactions contemplated

Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2019 Financial Results; Introduces Fiscal Year 2020 Revenue Guidance

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2019 Financial Results; Introduces Fiscal Year 2020 Revenue Guidance CANTON, Mass. (March 9, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Woun

ORGO / Organogenesis Holdings Inc. 10-K - Annual Report - 10-K

10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.

Description of Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K (File No. 001-37906) filed with the SEC on March 9, 2020)

EX-4.1 Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the capital stock of Organogenesis Holdings Inc. (the “Company,” “we,” “us,” and “our”) and the material provisions of our restated certificate of incorporation and our amended and restated bylaws, the amended and restated registration r

Fourth Amendment to Lease dated February 14, 2020 by and between Liberty Industrial Park and Organogenesis Inc. (incorporated by reference to Exhibit 10.41 to the Company’s Annual Report on Form 10-K (File No. 001-37906) filed with the SEC on March 9, 2020)

EX-10.41 Exhibit 10.41 FOURTH AMENDMENT TO LEASE (Liberty Industrial Park, LLC) THIS FOURTH AMENDMENT TO LEASE (“Fourth Amendment”) is made and entered into as of the 14th day of February, 2020, by and between LIBERTY INDUSTRIAL PARK, a California limited liability company (“Lessor”) and ORGANOGENESIS INC., a Delaware corporation (“Lessee”). R E C I T A L S: A. Lessor and ADVANCED BIOHEALING, Inc.

Second Amendment to Lease dated February 7, 2020 by and between Oxmoor Holdings, LLC and Organogenesis Inc. (incorporated by reference to Exhibit 10.42 to the Company’s Annual Report on Form 10-K (File No. 001-37906) filed with the SEC on March 9, 2020)

EX-10.42 Exhibit 10.42 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (the “Second Amendment”) is made effective and entered into on the 7th day of February, 2020 by and between Oxmoor Holdings, LLC, an Alabama limited liability company (“Landlord”), and Organogenesis Inc., a Delaware corporation (“Tenant”). Capitalized terms used but not otherwise defined herein shall have the meaning g

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (

Second Amendment to Credit Agreement entered into on February 14, 2020 and dated and effective as of February 13, 2020 among Organogenesis Holdings Inc., Organogenesis Inc. and Prime Merger Sub, LLC, collectively as borrower, and Silicon Valley Bank, in its capacity as the Issuing Lender and Swingline Lender, Silicon Valley Bank, as Administrative Agent, and Silicon Valley Bank and the other lenders listed therein, collectively as lenders (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on February 19, 2020)

EX-10.1 Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT This Second Amendment to Credit Agreement (this “Amendment”) dated and effective as of February 13, 2020 (the “Second Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (“Holdings”), ORGANOGENESIS INC., a Delaware corporation (“Organogenesis”) and PRIME MERGER SUB, LLC, a Delaware limited liability c

ORGO / Organogenesis Holdings Inc. / HIGHBRIDGE CAPITAL MANAGEMENT LLC - ORGANOGENESIS HOLDINGS INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Organogenesis Holdings Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate th

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C

Organogenesis Holdings Inc. Reports Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2019

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2019 CANTON, Mass. (January 13, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Spo

Regulation FD Disclosure, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2019 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C

Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation. References in this present

EX-99.1 Corporate Presentation December 2019 Exhibit 99.1 Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation. References in this presentation to the “Business Combination” refer to the consummation of the transactions contemplat

ORGO / Organogenesis Holdings Inc. / Ades Alan A. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02

ORGO / Organogenesis Holdings Inc. / Avista Acquisition Corp. - SC 13DA Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock

EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock CANTON, Mass., (November 21, 2019) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mark

Underwriting Agreement, dated November 21, 2019, by and among Credit Suisse Securities (USA) LLC and SVB Leerink LLC, as representatives of the underwriters named in Schedule A thereto.

EX-1.1 Exhibit 1.1 Execution Version 9,000,000 Shares Organogenesis Holdings Inc. Class A Common Stock, $0.0001 par value UNDERWRITING AGREEMENT November 21, 2019 Credit Suisse Securities (USA) LLC SVB LEERINK LLC As Representatives of the Several Underwriters c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010-3629 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12t

Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock CANTON, Mass., (November 19, 2019) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine market

Fee Letter Agreement dated November 19, 2019 by and among the Company, the Avista Funds and the Management Company

EX-10.1 Exhibit 10.1 November 19, 2019 Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 Attn: Gary S. Gillheeney, Sr., President and Chief Executive Officer Re:Fee Letter Agreement Ladies and Gentlemen: This fee letter agreement (the “Agreement”) confirms the agreement by and among Organogenesis Holdings Inc. (the “Company”), Avista Capital Partners IV, L.P. (“Avista IV”), Avist

9,000,000 Shares Class A Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233621 Prospectus Supplement (To Prospectus Dated September 23, 2019) 9,000,000 Shares Class A Common Stock We are offering 9,000,000 shares of our Class A common stock. Our Class A common stock is listed on The Nasdaq Capital Market under the symbol “ORGO.” On November 21, 2019, the last reported sale price of our Class

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2019 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (

SUBJECT TO COMPLETION, DATED NOVEMBER 19, 2019 PRELIMINARY PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED SEPTEMBER 23, 2019 9,000,000 Shares Class A Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233621 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2019 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (

First Amendment to Credit Agreement dated November 12, 2019 among Organogenesis Holdings Inc., Organogenesis Inc. and Prime Merger Sub, LLC, collectively as borrower, and Silicon Valley Bank, in its capacity as the Issuing Lender and Swingline Lender, Silicon Valley Bank, as Administrative Agent, and Silicon Valley Bank and the other lenders listed therein, collectively as lenders (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on November 15, 2019)

EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT This First Amendment to Credit Agreement (this “Amendment”) dated and effective as of November 12, 2019 (the “First Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (“Holdings”), ORGANOGENESIS INC., a Delaware corporation (“Organogenesis”) and PRIME MERGER SUB, LLC, a Delaware limited liability comp

ORGO / Organogenesis Holdings Inc. 10-Q - Quarterly Report - 10-Q

10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC. (Exact

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2019 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (

Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results CANTON, Mass. (November 12, 2019) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine ma

ORGO / Organogenesis Holdings Inc. CORRESP - -

CORRESP Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 September 19, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Organogenesis Holdings Inc. Registration Statement on Form S-3 File No. 333-233621 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securitie

Bylaws of Organogenesis Holdings Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-3/A (File No. 333-233621) filed with the SEC on September 16, 2019)

EX-3.2 Exhibit 3.2 BYLAWS ORGANOGENESIS HOLDINGS INC. (a Delaware corporation) Effective December 10, 2018 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Organogenesis Holdings Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as properly may come before such meeting shall be held at such place, ei

Certificate of Incorporation of Organogenesis Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-3/A (File No. 333-233621) filed with the SEC on September 16, 2019)

EX-3.1 Exhibit 3.1 CORRECTED CERTIFICATE OF INCORPORATION OF ORGANOGENESIS HOLDINGS INC. The Corporation is duly organized and existing under and by virtue of the Delaware General Corporation Law of the State of Delaware. DOES HEREBY CERTIFY: 1. The name of the Corporation is: Organogenesis Holdings Inc. 2. That a Certificate of Incorporation was filed by the Secretary of State of Delaware on Dece

ORGO / Organogenesis Holdings Inc. S-3/A - - S-3/A

S-3/A As filed with the Securities and Exchange Commission on September 16, 2019 Registration Statement No.

ORGO / Organogenesis Holdings Inc. CORRESP - -

CORRESP Seaport West 155 Seaport Boulevard Boston, MA 02210-2600 617 832 1000 main 617 832 7000 fax Stacie S.

ORGO / Organogenesis Holdings Inc. / Avista Acquisition Corp. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Powers of Attorney (included on the signature pages to the registration statement)

S-3 Table of Contents As filed with the Securities and Exchange Commission on September 4, 2019 Registration Statement No.

Form of Indenture

EX-4.1 Exhibit 4.1 ORGANOGENESIS HOLDINGS INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.01 Issuable in Series 6 Section 2.02 Esta

Unregistered Sales of Equity Securities

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 16, 2019 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Co

ORGO / Organogenesis Holdings Inc. / Avista Acquisition Corp. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.